Sharemaestro Newsreel

Judge Dismisses AstraZeneca’s Bid To Stop Maine Pharmacy Law

A federal court has dismissed AstraZeneca's attempt to block a Maine law that regulates drug companies' contracts with pharmacies. The US District Court for the District of Maine granted the state's motion to dismiss, upholding Chapter 103 of its insurance code. This law prohibits …

AbbVie Inc Stock (ABBV) Moved Up by 3.35% on Jul 28: A Full Analysis

AbbVie Inc (ABBV) saw its stock rise by 3.35% on July 28, outperforming the Pharmaceuticals & Medical Research sector. This strong performance was attributed to robust second-quarter earnings, significant growth in its immunology drugs Skyrizi and Rinvoq, and positive late-stage clinical trial data in …

Gilead Sciences stock may move 4.3% on August earnings report By Investing.com

Gilead Sciences Inc. (NYSE:GILD) stock is projected to move 4.3% following its upcoming August 4 earnings report, according to options data compiled by Bloomberg. Historical data indicates that the stock's actual movement has sometimes exceeded options traders' anticipation, with past earnings reports showing both …

Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial

Atea Pharmaceuticals announced positive results from its Phase 3 C-BEYOND clinical trial for a Hepatitis C antiviral therapy, showing it is non-inferior to Gilead Sciences' Epclusa. The experimental dual-drug combination achieved a 93.9% sustained virologic response rate at 24 weeks and demonstrated a strong …

Sanofi and Servier execs talk oncology: Pitches, Europe's position, and China's advantage

Executives from Sanofi and Servier discussed the evolving oncology licensing landscape, highlighting divergent approaches to assessing potential partnerships and the increasing competitive threat from China. They emphasized the need for European biotech companies to increase their speed and competitiveness, while also leveraging their strengths …

Amgen stock hits all-time high at 391.3 USD

Amgen Inc. (NASDAQ: AMGN) stock has reached an all-time high of $391.42, trading close to its InvestingPro Fair Value of $392.58. This achievement is backed by a 28.64% total return over the past year and a PEG ratio of 0.83, indicating strong investor confidence …

Cramer’s Mad Dash: Johnson & Johnson

Jim Cramer delivers his daily "Mad Dash" segment focusing on Johnson & Johnson. The article features a video clip of Cramer discussing the company, with the segment lasting 2 minutes and 36 seconds.

AstraZeneca's drug pipeine is splitting opinion among City analysts

AstraZeneca's drug pipeline is causing a divergence of opinions among City analysts, with Citibank upgrading its price target to 17,800p due to a solid second quarter and strong pipeline, while Deutsche Bank maintained a 'sell' rating at 11,500p. The company's shares were down 1.1% …

Pfizer (NYSE:PFE) Shares Gain Pre-Earnings as 7% Dividend Undergoes Cash-Flow Scrutiny

Pfizer (NYSE:PFE) stock saw a modest gain ahead of its Q2 earnings report, as investors scrutinize the sustainability of its nearly 7% dividend amidst cash flow pressures. Preliminary consensus estimates project a decline in second-quarter earnings per share compared to the previous year, and …

Eli Lilly tops new biopharma ranking on launch success, development speed

Eli Lilly has climbed to the top of Norstella’s inaugural Pipeline-to-Patient Productivity Index (P3i), ranking first among 25 biopharma companies for its efficiency in R&D, market access, and commercial performance over the last five years. The index highlights Lilly's strong launch performance, effective portfolio …

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

Johnson & Johnson has agreed to a $5.5 billion settlement to resolve tens of thousands of lawsuits alleging that its talc products caused ovarian cancer. The proposed deal, which needs acceptance from 95% of claimants, aims to conclude years of litigation, with payouts starting …

Barclays Adjusts Gilead Sciences Price Target to $145 From $155, Maintains Equalweight Rating

Barclays has adjusted its price target for Gilead Sciences (GILD) to $145, down from the previous $155, while reiterating an "Equalweight" rating on the stock. This update reflects a revised valuation perspective from the firm. The article also provides a brief company profile, detailing …

Barclays Adjusts Amgen Price Target to $360 From $350, Maintains Equalweight Rating

Barclays has increased its price target for Amgen (NASDAQ: AMGN) to $360 from $350, while reiterating an "Equalweight" rating on the stock. This adjustment reflects the firm's updated valuation of the biotechnology company. Amgen remains a leading biotechnology group focused on drug sales for …

Grifols increases revenue by 2.6% to EUR3.6 billion, and net profit by 28.7% to EUR227 million until June

Grifols reported an increase in revenue by 2.6% to EUR3.6 billion and a significant rise in net profit by 28.7% to EUR227 million for the period until June. The company specializes in therapeutic products, medical devices, and plasma-derived products, with primary markets in the …

Barclays Adjusts Merck & Co. Price Target to $150 From $140, Maintains Overweight Rating

Barclays has increased its price target for Merck & Co. (MRK) shares to $150, up from the previous $140. The firm is maintaining an "Overweight" rating on the stock. This adjustment reflects a positive outlook for the pharmaceutical company.

Barclays Adjusts Biogen Price Target to $200 From $185, Maintains Equalweight Rating

Barclays has increased its price target for Biogen Inc. (BIIB) to $200, up from the previous $185, while retaining an "Equalweight" rating on the stock. This adjustment reflects a revised analyst outlook on the pharmaceutical company. The article also lists recent analyst actions from …

Barclays Adjusts AbbVie PT to $300 From $275, Maintains Overweight Rating

Barclays has increased its price target for AbbVie (ABBV) to $300 from $275, while reiterating an Overweight rating on the stock. The adjustment reflects an updated outlook from the analytical firm regarding the pharmaceutical company's future performance. AbbVie specializes in therapeutic drug research and …

Sanofi (SNY) discloses $534M portfolio across 10 positions in latest 13F

Sanofi (SNY) has filed its latest 13F Holdings Report, revealing a U.S. equity portfolio valued at $534,041,662 across 10 distinct positions. The report confirms Sanofi as the sole institutional investment manager for these holdings, with the filing signed by Alexandra Roger, Head of Legal …

Johnson & Johnson offers up to $5.5 billion to settle baby powder cancer lawsuits | CNN Business

Johnson & Johnson has proposed a settlement of up to $5.5 billion to resolve approximately 76,000 lawsuits alleging its talcum powder products caused ovarian cancer. The company maintains that the lawsuits lack scientific merit and that its products are safe, despite mixed outcomes in …

New Iza-bren Approvals Underscore China's Rising Role In Bispecific ADCs

New approvals for Biokin’s Iza-bren, a first-in-class EGFRxHER3 bispecific ADC, for advanced nasopharyngeal carcinoma and recurrent or metastatic esophageal squamous cell carcinoma, highlight China's growing influence in this field. Biokin aims for global commercialization, leveraging its first-mover advantage and partnership with Bristol Myers Squibb. …

Empowered Funds LLC Lowers Position in Merck & Co., Inc. $MRK

Empowered Funds LLC reduced its stake in Merck & Co., Inc. by 26% in the first quarter, selling 178,382 shares but still retaining 507,815 shares valued at $61.1 million. Despite the reduction by this fund, institutional investors overall own 76.07% of Merck's stock. The …

Lazard Asset Management LLC Raises Stake in Bristol Myers Squibb Company $BMY

Lazard Asset Management LLC increased its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 23.7% in the first quarter, now owning 1,924,036 shares valued at $116.69 million. Other institutional investors like Vanguard Group Inc., State Street Corp, and Geode Capital Management LLC also significantly …

Empowered Funds LLC Sells 38,200 Shares of Amgen Inc. $AMGN

Empowered Funds LLC reduced its stake in Amgen Inc. by 32.0% in the first quarter, selling 38,200 shares and bringing its total holdings to $28.53 million. This comes amidst other institutional investors also adjusting their positions in the medical research company. Amgen's stock performance …

SCLX|Scilex Holding Co|Price:7.100|Chg%:+0.260

Scilex Holding Co (SCLX) is currently trading at $6.835, down 2.77%, with a market capitalization of $48.07 million. The company, focused on non-opioid pain management products, has high growth potential but weak fundamentals and is considered fairly valued in the Pharmaceuticals industry. Analysts have …

PFIZER: Q1 FY27 saw higher revenue and profit, with EPS up and strong equity despite exceptional costs

Pfizer reported higher revenue and net profit in Q1 FY27, with EPS increasing to ₹44.69. The company maintained a strong equity position despite exceptional costs in FY26 due to a Cipla agreement and labor code changes. This information is based on an interim report …

Johnson & Johnson (JNJ) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Johnson & Johnson (JNJ), identifying its major institutional holders like Vanguard, State Street, and BlackRock. It provides a breakdown of shareholder types, institutional holdings over several quarters, and recent shareholder activity with changes in holdings. The report …

PFE|Pfizer Inc|Price:24.660|Chg%:+0.120

This article provides a comprehensive overview of Pfizer Inc. (PFE), detailing its current stock performance, key financial figures, and analyst ratings. It highlights the company's strong fundamentals and high growth potential within the pharmaceuticals industry, noting that its valuation is considered fairly valued. The …

Earnings Preview: Amgen (AMGN) Q2 Earnings Expected to Decline

Johnson & Johnson (JNJ) Stock May Be 31% Undervalued As Myeloma Trial Results Impress

Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

AstraZeneca’s Q2 Earnings Prove It Doesn’t Need More M&A. The CEO Said So Himself.

AstraZeneca Stock: What We Thought of Earnings

Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

Gilead Sciences Inc (GILD) Financial Health: Profitability & Balance Sheet Analysis

Gilead Sciences Inc (GILD) has a strong financial health score of 8.91, ranking 29th out of 155 in the Pharmaceuticals industry, indicating stable financial status and high operating efficiency. The company reported a quarterly revenue of $6.96 billion, marking a 4.39% year-over-year increase, and …

Johnson And Johnson Talc Settlement Puts Colgate And Kimberly Clark Stock In Focus

Johnson & Johnson's proposed $5.5 billion talc settlement is impacting investor perceptions of litigation risk and competitive landscape in the baby and personal care market. This article examines how companies like Colgate-Palmolive and Kimberly-Clark, which operate in related spaces, might be affected. It also …